Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Time to Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $9.89 and last traded at $10.13, with a volume of 3986 shares changing hands. The stock had previously closed at $10.23.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research note on Wednesday, December 18th. B. Riley dropped their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Stephens reaffirmed an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC reissued a "buy" rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.14.

Bicycle Therapeutics Trading Down 7.4 %

The company has a market cap of $664.91 million, a price-to-earnings ratio of -2.93 and a beta of 1.12. The company has a fifty day moving average price of $12.53 and a two-hundred day moving average price of $18.61.

Remove Ads

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. During the same period in the previous year, the business earned ($1.16) earnings per share. The company's quarterly revenue was down 30.2% on a year-over-year basis. Sell-side analysts anticipate that Bicycle Therapeutics plc will post -3.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the acquisition, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. This represents a 11.52 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Santiago Arroyo sold 4,943 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the sale, the insider now owns 69,057 shares of the company's stock, valued at approximately $973,013.13. The trade was a 6.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,677 shares of company stock worth $392,413 over the last three months. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its stake in Bicycle Therapeutics by 406.2% in the fourth quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company's stock valued at $63,769,000 after buying an additional 3,655,101 shares during the period. Baker BROS. Advisors LP increased its stake in Bicycle Therapeutics by 15.8% in the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock valued at $152,395,000 after purchasing an additional 1,485,397 shares in the last quarter. Fcpm Iii Services B.V. raised its holdings in Bicycle Therapeutics by 47.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after purchasing an additional 1,112,369 shares during the period. Long Focus Capital Management LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth $7,603,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics in the 3rd quarter valued at $10,028,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.